PortalPublikationenQuality of life measurement in rosacea: Position statement o...

Quality of life measurement in rosacea: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Standard

Quality of life measurement in rosacea: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. / Chernyshov, P V; Finlay, A Y; Tomas-Aragones, L; Steinhoff, M; Manolache, L; Pustisek, N; Dessinioti, C; Svensson, A; Marron, S E; Bewley, A; Salavastru, C; Dréno, B; Suru, A; Koumaki, D; Linder, D; Evers, A W M; Abeni, D; Augustin, M; Salek, S S; Nassif, A; Bettoli, V; Szepietowski, J С; Zouboulis, C C.

in: J EUR ACAD DERMATOL, Jahrgang 37, Nr. 5, 05.2023, S. 954-964.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Leitlinie, Empfehlung, Stellungnahme › Forschung › Begutachtung

Harvard

Chernyshov, PV, Finlay, AY, Tomas-Aragones, L, Steinhoff, M, Manolache, L, Pustisek, N, Dessinioti, C, Svensson, A, Marron, SE, Bewley, A, Salavastru, C, Dréno, B, Suru, A, Koumaki, D, Linder, D, Evers, AWM, Abeni, D, Augustin, M, Salek, SS, Nassif, A, Bettoli, V, Szepietowski, JС & Zouboulis, CC 2023, 'Quality of life measurement in rosacea: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa', J EUR ACAD DERMATOL, Jg. 37, Nr. 5, S. 954-964. https://doi.org/10.1111/jdv.18918

APA

Chernyshov, P. V., Finlay, A. Y., Tomas-Aragones, L., Steinhoff, M., Manolache, L., Pustisek, N., Dessinioti, C., Svensson, A., Marron, S. E., Bewley, A., Salavastru, C., Dréno, B., Suru, A., Koumaki, D., Linder, D., Evers, A. W. M., Abeni, D., Augustin, M., Salek, S. S., ... Zouboulis, C. C. (2023). Quality of life measurement in rosacea: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J EUR ACAD DERMATOL, 37(5), 954-964. https://doi.org/10.1111/jdv.18918

Vancouver

Chernyshov PV, Finlay AY, Tomas-Aragones L, Steinhoff M, Manolache L, Pustisek N et al. Quality of life measurement in rosacea: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J EUR ACAD DERMATOL. 2023 Mai;37(5):954-964. https://doi.org/10.1111/jdv.18918

Bibtex

@article{da2dc8d0531e4533a5528d4156f1b9f0,
title = "Quality of life measurement in rosacea: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa",
abstract = "The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non-dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient-Oriented Outcomes and ARHS recommend the use of the dermatology-specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea-specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.",
keywords = "Humans, Hidradenitis Suppurativa/therapy, Quality of Life, Venereology, Dermatology, Acne Vulgaris, Rosacea/therapy",
author = "Chernyshov, {P V} and Finlay, {A Y} and L Tomas-Aragones and M Steinhoff and L Manolache and N Pustisek and C Dessinioti and A Svensson and Marron, {S E} and A Bewley and C Salavastru and B Dr{\'e}no and A Suru and D Koumaki and D Linder and Evers, {A W M} and D Abeni and M Augustin and Salek, {S S} and A Nassif and V Bettoli and Szepietowski, {J С} and Zouboulis, {C C}",
note = "{\textcopyright} 2023 European Academy of Dermatology and Venereology.",
year = "2023",
month = may,
doi = "10.1111/jdv.18918",
language = "English",
volume = "37",
pages = "954--964",
journal = "J EUR ACAD DERMATOL",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Quality of life measurement in rosacea: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

AU - Chernyshov, P V

AU - Finlay, A Y

AU - Tomas-Aragones, L

AU - Steinhoff, M

AU - Manolache, L

AU - Pustisek, N

AU - Dessinioti, C

AU - Svensson, A

AU - Marron, S E

AU - Bewley, A

AU - Salavastru, C

AU - Dréno, B

AU - Suru, A

AU - Koumaki, D

AU - Linder, D

AU - Evers, A W M

AU - Abeni, D

AU - Augustin, M

AU - Salek, S S

AU - Nassif, A

AU - Bettoli, V

AU - Szepietowski, J С

AU - Zouboulis, C C

N1 - © 2023 European Academy of Dermatology and Venereology.

PY - 2023/5

Y1 - 2023/5

N2 - The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non-dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient-Oriented Outcomes and ARHS recommend the use of the dermatology-specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea-specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.

AB - The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non-dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient-Oriented Outcomes and ARHS recommend the use of the dermatology-specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea-specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.

KW - Humans

KW - Hidradenitis Suppurativa/therapy

KW - Quality of Life

KW - Venereology

KW - Dermatology

KW - Acne Vulgaris

KW - Rosacea/therapy

U2 - 10.1111/jdv.18918

DO - 10.1111/jdv.18918

M3 - Guideline, recommendation, statement

C2 - 36744752

VL - 37

SP - 954

EP - 964

JO - J EUR ACAD DERMATOL

JF - J EUR ACAD DERMATOL

SN - 0926-9959

IS - 5

ER -